About: Early impact of COVID‐19 on transplant center practices and policies in the United States

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Early impact of COVID‐19 on transplant center practices and policies in the United States Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Early impact of COVID‐19 on transplant center practices and policies in the United States
Creator	Avery, Robin Boyarsky, Brian Chiang, Po-Yu Durand, Christine Garonzik-Wang, Jacqueline Getsin, Samantha Jackson, Kyle Kernodle, Amber Massie, Allan Rasmussen, Pilsum Segev, Dorry Teresa, \| Van, Sarah Werbel, William
Source	Medline; PMC
abstract	COVID‐19 is a novel, rapidly changing pandemic: consequently, evidence‐based recommendations in solid organ transplantation (SOT) remain challenging and unclear. To understand the impact on transplant activity across the United States, and center‐level variation in testing, clinical practice, and policies, we conducted a national survey between March 24, 2020 and March 31, 2020 and linked responses to the COVID‐19 incidence map. Response rate was a very high 79.3%, reflecting a strong national priority to better understand COVID‐19. Complete suspension of live donor kidney transplantation was reported by 71.8% and live donor liver by 67.7%. While complete suspension of deceased donor transplantation was less frequent, some restrictions to deceased donor kidney transplantation were reported by 84.0% and deceased donor liver by 73.3%; more stringent restrictions were associated with higher regional incidence of COVID‐19. Shortage of COVID‐19 tests was reported by 42.5%. Respondents reported a total of 148 COVID‐19 recipients from <1 to >10 years posttransplant: 69.6% were kidney recipients, and 25.0% were critically ill. Hydroxychloroquine (HCQ) was used by 78.1% of respondents; azithromycin by 46.9%; tocilizumab by 31.3%, and remdesivir by 25.0%. There is wide heterogeneity in center‐level response across the United States; ongoing national data collection, expert discussion, and clinical studies are critical to informing evidence‐based practices.
has issue date	2020-05-10(xsd:dateTime)
bibo:doi	10.1111/ajt.15915
bibo:pmid	32282982
has license	no-cc
sha1sum (hex)	4ce91aededb8c26fe81e94119716361cd584d378
schema:url	https://doi.org/10.1111/ajt.15915
resource representing a document's title	Early impact of COVID‐19 on transplant center practices and policies in the United States
has PubMed Central identifier	PMC7262146
has PubMed identifier	32282982
schema:publication	Am J Transplant
resource representing a document's body	covid:4ce91aededb8c26fe81e94119716361cd584d378#body_text
is schema:about of	named entity 'linked' named entity 'donor' named entity 'DONOR LIVER' named entity 'TRANSPLANT' named entity 'RESPONSES' named entity 'RECOMMENDATIONS' named entity 'TESTING' named entity 'COVID-19' named entity 'map' named entity 'high' named entity 'conducted' named entity 'liver' named entity 'COVID-19' named entity 'kidney transplantation' named entity 'SOT' named entity 'cumulative incidence' named entity 'LAS' named entity 'status 1' named entity 'COVID-19' named entity 'COVID-19 pandemic' named entity 'COVID' named entity 'United States' named entity 'COVID' named entity 'SOT' named entity 'significance level' named entity 'United States' named entity 'COVID-19 pandemic' named entity 'dialysis' named entity 'March 24' named entity 'nosocomial' named entity 'American Journal of Transplantation' named entity 'US Census' named entity 'SOT' named entity 'COVID-19' named entity 'SOT' named entity 'COVID' named entity 'evidence based' named entity 'exact test' named entity 'tumors' named entity 'cumulative incidence' named entity 'COVID-19' named entity 'infection' named entity 'COVID' named entity 'Stata' named entity 'SOT' named entity 'Qualtrics' named entity 'pancreas transplantation' named entity 'COVID' named entity 'lung' named entity 'United States' named entity 'United States' named entity 'SOT' named entity 'transplant surgeons' named entity 'decision-making' named entity 'solid organ transplantation' named entity 'crossmatch' named entity 'COVID-19' named entity 'COVID-19' named entity 'Pancreas transplantation' named entity 'SOT' named entity 'COVID' named entity 'COVID-19 testing' named entity 'COVID' named entity 'ICU beds' named entity 'MERS-CoV' named entity 'probability' named entity 'operating room' named entity 'MELD'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software